The Potential for Pharmacokinetic Interactions Between Cannabis Products and Conventional Medications

@article{Qian2019ThePF,
  title={The Potential for Pharmacokinetic Interactions Between Cannabis Products and Conventional Medications},
  author={Yuli Qian and B. Gurley and J. Markowitz},
  journal={Journal of Clinical Psychopharmacology},
  year={2019},
  volume={39},
  pages={462 - 471}
}
Supplemental digital content is available in the text. Abstract Purpose Increased cannabis use and recent drug approvals pose new challenges for avoiding drug interactions between cannabis products and conventional medications. This review aims to identify drug-metabolizing enzymes and drug transporters that are affected by concurrent cannabis use and, conversely, those co-prescribed medications that may alter the exposure to one or more cannabinoids. Methods A systematic literature search was… Expand
23 Citations
Potential Adverse Drug Events with Tetrahydrocannabinol (THC) Due to Drug–Drug Interactions
  • J. Brown
  • Medicine
  • Journal of clinical medicine
  • 2020
  • 5
  • PDF
Natural Products as Modulators of CES1 Activity
  • 1
Serious adverse effects of cannabidiol (CBD): a review of randomized controlled trials
  • 9
Access to cannabidiol without a prescription: A cross-country comparison and analysis.
  • 1
...
1
2
3
...